All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F15%3A10312475" target="_blank" >RIV/00216208:11140/15:10312475 - isvavai.cz</a>

  • Alternative codes found

    RIV/00669806:_____/15:10312475

  • Result on the web

    <a href="http://dx.doi.org/10.1182/blood-2015-06-651562" target="_blank" >http://dx.doi.org/10.1182/blood-2015-06-651562</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1182/blood-2015-06-651562" target="_blank" >10.1182/blood-2015-06-651562</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation

  • Original language description

    To analyze the influence of distinct combinations ofmolecular aberrations on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for cytogenetically normal acute myeloid leukemia (CN-AML), a retrospective registry analysis was performed on 702 adults undergoing HSCT in first complete remission (CR). Patients were grouped according to presence or absence of NPM1 mutations (NPM1mut) and FLT3 internal tandem duplications (FLT3-ITD). Double-negative patients were evaluated for mutationsof the CCAAT/enhancer binding protein a gene (CEBPa). The influence of genotypes on relapse, non-relapse mortality, leukemia-free survival (LFS) and overall survival (OS), and a prognostic classification combining NPM1/FLT3-ITD profile and classical riskfactors were calculated. Two-year OS fromHSCTwas 8165% in NPM1mut/FLT3wt, 7563%in NPM1wt/FLT3wt, 6663%in NPM1mut/FLT3-ITD, and 54 6 7% in NPM1wt/FLT3-ITD (P 5 .003). Analysis of CEBPa among patients with NPM1wt/FLT3wt revealed excellent

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2015

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Blood

  • ISSN

    0006-4971

  • e-ISSN

  • Volume of the periodical

    126

  • Issue of the periodical within the volume

    17

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    8

  • Pages from-to

    2062-2069

  • UT code for WoS article

    000366389200018

  • EID of the result in the Scopus database

    2-s2.0-84944931277